On August 21, 2026, a trial update was recorded for bivalirudin under study NCT04278404. The trial is titled "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)." Its current status is listed as recruiting. No phase designation was provided for this study in the available record.
The POPS trial examines understudied drugs, including bivalirudin, as administered to children according to standard of care practices. This update reflects only the recruitment status as of the date listed and does not include any outcome or results data. No efficacy or safety findings have been reported as part of this update.
Bivalirudin remains an approved compound. This trial update is procedural and pertains solely to the study's recruitment status, not to any new clinical results or determinations about the drug's use in pediatric populations. Readers seeking additional context on bivalirudin can consult the compound overview for further background information.